New mRNA vaccine shows promise against common virus in early trial

NCT ID NCT04232280

First seen May 16, 2026 · Last updated May 16, 2026

Summary

This study tested an experimental mRNA vaccine (mRNA-1647) to see if it is safe and triggers an immune response against cytomegalovirus (CMV), a common virus that can cause serious problems in newborns and people with weak immune systems. The trial included 315 healthy adults aged 18-40, some already exposed to CMV and some not. Researchers measured side effects and antibody levels after vaccination to find the best dose.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Alliance for Multispecialty Research

    Lexington, Kentucky, 40509, United States

  • Aventiv Research Inc

    Columbus, Ohio, 43213-6523, United States

  • Benchmark Research

    Sacramento, California, 95864, United States

  • Crossroads Clinical Research

    Victoria, Texas, 77901, United States

  • Foothill Family Clinic

    Salt Lake City, Utah, 84109, United States

  • Foothill Family Clinic-South Clinic

    Salt Lake City, Utah, 84121, United States

  • Johnson County Clin-Trials

    Lenexa, Kansas, 66219, United States

  • Optimal Research

    Peoria, Illinois, 61614, United States

  • Tekton Research Inc

    Austin, Texas, 78745, United States

Conditions

Explore the condition pages connected to this study.